Kondo S - Search Results

1

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study.

Kato N, Kudo M, Tsuchiya K, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Okano N, Ikeda M, Morimoto M, Kuroda S, Kimura A. Kato N, et al. Among authors: kondo s. Hepatol Res. 2023 May;53(5):409-416. doi: 10.1111/hepr.13876. Epub 2023 Jan 23. Hepatol Res. 2023. PMID: 36601972

2

Spontaneous regression of hepatocellular carcinoma.

Kondo S, Okusaka T, Ueno H, Ikeda M, Morizane C. Kondo S, et al. Int J Clin Oncol. 2006 Oct;11(5):407-11. doi: 10.1007/s10147-006-0591-4. Int J Clin Oncol. 2006. PMID: 17058140

3

Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?

Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T. Hashimoto K, et al. Among authors: kondo s. Oncology. 2009;77(3-4):217-23. doi: 10.1159/000236022. Epub 2009 Sep 4. Oncology. 2009. PMID: 19729980

4

Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.

Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N. Iwasa S, et al. Among authors: kondo s. Jpn J Clin Oncol. 2010 Apr;40(4):313-8. doi: 10.1093/jjco/hyp173. Epub 2010 Jan 4. Jpn J Clin Oncol. 2010. PMID: 20047862

5

[Chemotherapy].

Ikeda M, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Okusaka T. Ikeda M, et al. Among authors: kondo s. Gan To Kagaku Ryoho. 2010 Mar;37(3):408-12. Gan To Kagaku Ryoho. 2010. PMID: 20332676 Review. Japanese.

6

[Hepatocellular carcinoma].

Kondo S, Ueno H, Morizane C, Okusaka T. Kondo S, et al. Gan To Kagaku Ryoho. 2010 Jul;37(7):1219-23. Gan To Kagaku Ryoho. 2010. PMID: 20647702 Japanese.

7

Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.

Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A. Suzuki E, et al. Among authors: kondo s. Oncology. 2010;79(1-2):39-45. doi: 10.1159/000318020. Epub 2010 Nov 10. Oncology. 2010. PMID: 21063134

8

Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

Kaida M, Morita-Hoshi Y, Soeda A, Wakeda T, Yamaki Y, Kojima Y, Ueno H, Kondo S, Morizane C, Ikeda M, Okusaka T, Takaue Y, Heike Y. Kaida M, et al. Among authors: kondo s. J Immunother. 2011 Jan;34(1):92-9. doi: 10.1097/CJI.0b013e3181fb65b9. J Immunother. 2011. PMID: 21150717 Clinical Trial.

9

Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.

Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S, Satake M, Arai Y. Iwasa S, et al. Among authors: kondo s. Jpn J Clin Oncol. 2011 Jun;41(6):770-5. doi: 10.1093/jjco/hyr037. Epub 2011 Apr 1. Jpn J Clin Oncol. 2011. PMID: 21459893

10

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.

Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T. Morizane C, et al. Among authors: kondo s. Cancer Chemother Pharmacol. 2012 Apr;69(4):957-64. doi: 10.1007/s00280-011-1786-6. Epub 2011 Nov 26. Cancer Chemother Pharmacol. 2012. PMID: 22120961 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,627 results

Search Page